<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic rhinosinusitis with nasal polyposis: Management and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic rhinosinusitis with nasal polyposis: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic rhinosinusitis with nasal polyposis: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathleen M Buchheit, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric H Holbrook, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anju T Peters, MD, MSCI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Deschler, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1776591712"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic rhinosinusitis (CRS) is defined as a complex inflammatory condition involving the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer. It is estimated to affect up to 5 percent of the population. CRS is divided into CRS <strong>with</strong> nasal polyps (CRSwNP) and CRS <strong>without</strong> NP (CRSsNP), which are distinguished by the presence or absence of nasal polyps. CRSwNP represents approximately one-third of all CRS cases. Symptoms associated with CRSwNP include loss of the sense of smell (anosmia), nasal obstruction or blockage, anterior or posterior nasal drainage, and facial pressure [<a href="#rid1">1</a>]. The disorder is associated with significant medical resource consumption and impairments in quality of life, especially during acute exacerbations [<a href="#rid2">2,3</a>].</p><p>This topic will review the medical and surgical management of CRSwNP. The clinical manifestations and diagnostic criteria for CRS are discussed separately. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p>The management and prognosis of chronic rhinosinusitis <strong>without</strong> nasal polyps are also presented separately. (See  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H56748123"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>The primary goal in treating patients with CRSwNP is to reduce sinonasal symptoms and improve quality of life while minimizing medication adverse effects. Medical management of CRSwNP attempts to control the underlying inflammation that drives the growth of polyp tissue and the development of symptoms. Sinus surgery is used when initial medical management is not adequately effective. Many patients with CRSwNP require multiple therapeutic interventions to manage their symptoms adequately and need long-term and potentially indefinite treatment.</p><p class="headingAnchor" id="H3204660738"><span class="h1">IMPORTANT COMPONENTS OF CARE</span></p><p class="headingAnchor" id="H3259079965"><span class="h2">Patient education</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Setting realistic expectations </strong>–<strong><em> </em></strong>It is helpful to set expectations with patients and explain that treatments for CRSwNP are intended to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improve quality of life by reducing and occasionally eliminating symptoms</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevent exacerbations requiring treatment with oral glucocorticoids and antibiotics, as both may have significant long-term adverse effects</p><p></p><p class="bulletIndent1">However, available medical and surgical therapies rarely cure CRSwNP. Even if symptoms are completely controlled, medical therapy must be continued to prevent recurrence. Similarly, patients who undergo functional endoscopic sinus surgery (FESS) to remove polyp tissue still require diligent postoperative follow-up and medical treatment going forward to prevent regrowth of polyps [<a href="#rid4">4,5</a>]. For many patients, lifelong therapy will be needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Teaching proper use of intranasal corticosteroids </strong>– There are multiple intranasal corticosteroid (INCS) delivery options, including nasal sprays, irrigations/drops, and exhalation delivery system (EDS). Each requires specific patient education for proper use. Patients may not know how to use their INCS correctly, despite having a long history of CRSwNP. The patient's technique should be reviewed and correct technique carefully demonstrated for each type of INCS delivery system used. Reduction in local adverse effects of INCS (nasal irritation) can often be achieved with proper delivery technique [<a href="#rid6">6</a>] (see  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Optimal use'</a>). It is also important to counsel patients not to expect immediate results with INCS. Rather, improvement may be gradual, and INCS should be used for at least one month before assessing efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adherence </strong>–<strong> </strong>A critical aspect of treatment success is establishing a daily routine of sinus care to which the patient can adhere long term. Barriers to use of medications should be addressed at each visit. If a medication is not subjectively or objectively improving a patient's symptoms after a three-month trial, it should be stopped. An exception to this is the biologic therapies, as some patients may need longer than three months to respond [<a href="#rid7">7</a>]. When a therapy is efficacious, patients should be educated about the need for long-term adherence to prevent relapse of symptoms [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H501634770"><span class="h2">Multidisciplinary collaboration</span><span class="headingEndMark"> — </span>At initial presentation, all patients with suspected CRSwNP should undergo nasal endoscopy, preferably by an otolaryngologist, to confirm the diagnosis and rule out other causes of nasal congestion and anosmia. If an otolaryngologist is not available and polyps are not clearly visible in the nasal cavities, the diagnosis should be confirmed by computed tomography (CT) to demonstrate the presence of polyps, as required for definitive diagnosis. Once the diagnosis is confirmed, treatment can be started by a generalist but usually requires the input of allergy/immunology and/or otolaryngology specialists. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3413337117"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Upon initiation of treatment, patients should be monitored at regular intervals. We usually ask patients to return three months after initiation of therapy and then every three to six months thereafter until symptoms are adequately managed. At each visit, we assess sinonasal symptoms and quality of life, perform a nasal exam (endoscopic if possible), and review any use of oral glucocorticoids or antibiotics for exacerbations. We use validated symptom questionnaires such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsinonasaltest.wustl.edu%2F&amp;token=ucDrxnLuYNidf73NHuLMBRTVpp4sxVxKfd7KHWEY5Ccf0So3OUW7xDw%2BNOGjp6mn&amp;TOPIC_ID=121195" target="_blank">Sino-Nasal Outcomes Test (SNOT-22)</a> to assess symptom severity of CRS-related quality of life [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1966847897"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Our approach is consistent with treatment guidelines and practice parameters published by professional otolaryngology and allergy groups worldwide [<a href="#rid6">6,7,10-15</a>]. The pace at which we move through this series of interventions depends upon how symptomatic the patient is  (<a class="graphic graphic_algorithm graphicRef141882" href="/d/graphic/141882.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Upon initial presentation, we assess the patient for coexisting disorders that may alter treatment. (See <a class="local">'Coexisting disorders that may impact treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial treatment for nearly all patients includes medical management with intranasal corticosteroids (INCS), delivered one of several ways, and nasal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> irrigation. The intensity of INCS can be increased by changing the method of delivery. (See <a class="local">'Intranasal corticosteroids'</a> below and <a class="local">'Nasal saline irrigations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the nasal passages are completely obstructed, a short course of oral glucocorticoids can temporarily shrink polyp tissue and allow better access for topical therapies. Similarly, if there is purulent drainage, we treat for concomitant bacterial sinusitis with oral antibiotics, with culture-directed therapy when possible. (See <a class="local">'Oral glucocorticoids for complete obstruction or severe symptoms'</a> below and <a class="local">'Oral antibiotics for superimposed infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients, we offer sinus surgery when there is insufficient response to standard medical management. (See <a class="local">'Surgical management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with other indications for a biologic therapy (eg, severe asthma, chronic spontaneous urticaria, or contraindications for undergoing surgery), one of three biologic therapies can be prescribed. We also offer biologic therapies to patients whose polyps have regrown after an initial surgery. (See <a class="local">'Biologic therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H1334186831"><span class="h1">COEXISTING DISORDERS THAT MAY IMPACT TREATMENT</span><span class="headingEndMark"> — </span>There are several disorders that may present with or include CRSwNP that are important to identify, either through directed patient history or further specific evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspirin-exacerbated respiratory disease</strong> <strong>(AERD)</strong> – AERD should be suspected in patients with severe CRSwNP who have concomitant asthma and intolerance of nonsteroidal antiinflammatory drugs (NSAIDs). The prevalence of AERD among patients with CRSwNP is estimated at 10 percent [<a href="#rid16">16</a>]. NSAID intolerance most commonly presents as sudden worsening of nasal congestion, facial flushing, conjunctival injection, and/or bronchospasm one to two hours after ingesting <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or other NSAIDs, although patients may be unaware of the condition because the symptoms are similar to those of CRS and asthma. Supervised NSAID challenge is sometimes required to determine if the patient has intolerance. One reason for distinguishing AERD is that treatment may include aspirin desensitization and daily aspirin therapy, which is only useful in patients with NSAID intolerance. Sinus surgery is often performed before aspirin desensitization in a coordinated fashion. Preemptive surgery decreases the load of inflammatory tissue, thus making aspirin desensitization safer. It also prevents the need to interrupt aspirin therapy if surgery is needed after the patient has been desensitized and started on daily aspirin. The clinical manifestations and management of AERD are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic rhinitis and/or asthma</strong> – In addition to these specific disorders, many patients with CRSwNP have asthma, allergic rhinitis, or both. Comorbid asthma is present in approximately one-half of patients with CRSwNP in some populations [<a href="#rid17">17,18</a>]. Atopy, as defined as one or more positive skin tests to inhalant allergens, is present in &gt;60 percent of patients with CRSwNP [<a href="#rid17">17,19</a>]. However, there may be significant geographic differences worldwide. In a study of patients in China, only 9 percent had coexistent asthma [<a href="#rid20">20</a>]. Some of the therapies for asthma and allergic rhinitis overlap with those for CRSwNP, and all three of these disorders are often driven by type 2 inflammation. The management of these problems is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic fungal rhinosinusitis</strong> (<strong>AFRS)</strong> – AFRS presents with CRSwNP and should be suspected in patients who have characteristic findings on sinus computed tomography (CT; ie, one or more opacified sinuses containing hyperattenuated areas  (<a class="graphic graphic_diagnosticimage graphicRef77812" href="/d/graphic/77812.html" rel="external">image 1</a>)), the presence of eosinophilic mucin on biopsy of sinus contents, pathology showing fungal hyphae and degranulating eosinophils, and evidence of immunoglobulin E (IgE) mediated allergy to fungi. The prevalence of AFRS among patients with CRSwNP has been estimated at 8 percent, although there is wide geographic variability [<a href="#rid21">21</a>]. Endoscopic sinus surgery is required early in the management of most patients. The diagnosis and management of AFRS are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/101017.html" rel="external">"Allergic fungal rhinosinusitis"</a>.)</p><p></p><p>There are also distinct disorders that may present with CRSwNP but should be detected as early as possible because treatment and prognostic implications are different:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic granulomatosis with polyangiitis (EGPA) –</strong> EGPA usually presents with asthma, CRS (often with nasal polyposis), skin nodules, and peripheral neuropathy. It is a multisystem vasculitis, and other manifestations may include peripheral eosinophilia, weight loss, fever, myalgia, arthralgia, pulmonary opacities, cardiomyopathy, kidney disease, and gastrointestinal involvement. (See  <a class="medical medical_review" href="/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cystic fibrosis (CF)</strong> – In children, the finding of nasal polyposis should prompt consideration of possible CF. The incidence of CRSwNP in patients with CF has been estimated to be above 90 percent [<a href="#rid22">22,23</a>]. Patients with concomitant pneumonias or other features of CF  (<a class="graphic graphic_table graphicRef76253" href="/d/graphic/76253.html" rel="external">table 1</a>) should undergo specific testing, as detailed separately. (See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Sinus and nasopharyngeal disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary ciliary dyskinesia (PCD) –</strong> PCD is a congenital disorder caused by several defects, or complete absence of, cilia, leading to impaired mucosal clearance. Nasal polyposis is frequently present, often involving the maxillary and ethmoid sinuses. A history of neonatal respiratory distress, early-onset and persistent, productive cough, chronic otitis media, and/or a laterality defect (eg, situs inversus or ambiguous) should raise a strong clinical suspicion for PCD. (See  <a class="medical medical_review" href="/d/html/4338.html" rel="external">"Primary ciliary dyskinesia (immotile-cilia syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare nasal tumors</strong> – The identification of a polyp on exam alone should not automatically imply a benign inflammatory disease. Inflammatory nasal polyps, like those seen in CRSwNP, are usually bilateral, with surrounding mucosal swelling and abnormal (ie, thick or discolored) mucus. However, patients with unilateral nasal polyps or polyps with an unusual appearance should be referred to an otolaryngologist for evaluation of benign or malignant tumors [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/7535.html" rel="external">"Etiologies of nasal obstruction: An overview", section on 'Tumors'</a>.)</p><p></p><p class="headingAnchor" id="H292568980"><span class="h1">INITIAL THERAPIES FOR ALL PATIENTS</span></p><p class="headingAnchor" id="H2353593578"><span class="h2">Nasal saline irrigations</span><span class="headingEndMark"> — </span>We instruct patients to perform daily or twice-daily, high-volume (&gt;200 mL per nostril) nasal irrigations with a <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solution, in agreement with multiple consensus statements [<a href="#rid11">11,12,15</a>]. We recommend this for all patients with CRSwNP who can tolerate it and are not completely obstructed. Saline irrigations thin and flush out mucus, inflammatory debris, irritants, and allergens and improve mucociliary function.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique </strong>– There are multiple devices available for nasal irrigation, including squeeze bottles and neti pots. Patients can make their own <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solution or purchase commercially prepared solutions. High-volume (&gt;200 mL per nostril) saline irrigations are more effective than low-volume nasal saline sprays [<a href="#rid25">25-28</a>]. Patient instructions for saline irrigations are provided  (<a class="graphic graphic_table graphicRef71059" href="/d/graphic/71059.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety</strong> – Nasal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> irrigation is low risk and well tolerated by most patients. Most complaints are related to nasal drainage after irrigation and Eustachian tube obstruction or irritation. Eustachian tube complaints can be reduced by instructing patients to allow irrigation to pass into the oropharynx and out the mouth by keeping the throat and mouth relaxed. In addition, avoiding nose blowing for approximately 15 minutes after irrigation will decrease the potential for auto-insufflating the Eustachian tubes with saline. Patients should be instructed on how to ensure the device is clean (ie, sterilizing devices and adhering to replacement instructions as suggested by device manufacturers). Tap water or well water should not be used for sinus irrigations unless it is boiled first [<a href="#rid29">29,30</a>]. Transmission of life-threatening infections through nonsterilized water has been reported, as discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Nasal saline'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unclear benefit of additives</strong> – Surfactants to disrupt biofilms have been added to nasal irrigations, although there is inadequate evidence of benefit, and a possible adverse effect is reduction in sense of smell [<a href="#rid31">31-34</a>].</p><p></p><p class="headingAnchor" id="H3427827640"><span class="h2">Intranasal corticosteroids</span><span class="headingEndMark"> — </span>Guidelines and consensus statements recommend topical intranasal corticosteroids (INCS) as first-line treatment for CRSwNP [<a href="#rid11">11,14,35</a>]. We typically start with an INCS delivered via nasal spray, many of which are available without a prescription  (<a class="graphic graphic_table graphicRef55833" href="/d/graphic/55833.html" rel="external">table 3</a>). There are several other delivery systems in addition to nasal sprays, including rinses/irrigations, drops, and an exhalation-driven delivery system (EDS). Less common means of delivery include nasal nebulization and local injections.</p><p class="headingAnchor" id="H146560274"><span class="h3">The importance of proper technique</span><span class="headingEndMark"> — </span>Many patients have already been using INCS nasal sprays for symptoms of nasal congestion prior to a formal diagnosis of CRSwNP, but they often are not using optimal technique  (<a class="graphic graphic_figure graphicRef141563" href="/d/graphic/141563.html" rel="external">figure 1</a>). In addition, some patients with severe CRSwNP may be so obstructed that they cannot use an INCS. In this setting, a short course of oral glucocorticoids can be given to temporarily relieve obstruction so that topical therapies can be applied. (See <a class="local">'Oral glucocorticoids for complete obstruction or severe symptoms'</a> below.)</p><p>If symptoms do not adequately improve after one to three months of therapy, we consider changing delivery modalities to a nasal corticosteroid irrigation or EDS, depending on patient preference and cost/availability of these options for the patient.</p><p class="headingAnchor" id="H38323132"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Based on a systematic review, practice parameters for the medical management of CRSwNP recommend the use of INCS delivered by spray, irrigation, or EDS (rather than no INCS) for patients with CRSwNP, although this was based on low certainty of evidence given the small-to-moderate treatment effect size [<a href="#rid10">10</a>]. Numerous studies and meta-analyses also show general improvement in sinonasal symptoms, polyp size reduction, and quality of life with INCS for CRSwNP, but the benefit is often modest [<a href="#rid36">36-38</a>].</p><p class="headingAnchor" id="H2897305856"><span class="h4">Comparison of different delivery systems</span><span class="headingEndMark"> — </span>When patients do not achieve adequate relief from INCS nasal sprays, we typically change to either irrigations or EDS. Head-to-head clinical trials comparing the three delivery systems have not been performed, but standard INCS sprays may not reach target regions, such as the ostiomeatal complex and middle meatus, where polyps form [<a href="#rid39">39-41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A 2022 systematic review and network meta-analysis analyzed randomized controlled trials of different INCS delivery systems based on sinus-related quality of life (Sino-Nasal Outcomes Test [SNOT-22]) scores and nasal obstruction symptoms [<a href="#rid42">42</a>]. A minimum clinically important difference in the SNOT-22 score is a reduction of 8.9 points. Reductions were -3.63 (95% CI -9.27 to 2.04) with nasal sprays, -6.83 (95% CI -11.94 to -1.71) with irrigations, and -7.86 (-14.64 to -1.08) with EDS. The level of certainty in the evidence was low or very low. No differences in adverse effects were noted [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct evidence that EDS provides benefit beyond standard nasal sprays is limited, although, in a post-hoc sensitivity analysis of pooled data from two studies of EDS-fluticasone [<a href="#rid43">43,44</a>], 45 percent of patients were using standard INCS sprays at study entry, and these patients had comparable improvement to those not on INCS sprays initially, suggesting that EDS did result in additional symptom control [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H1953829228"><span class="h5">Nasal sprays</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available preparations</strong> <strong>and dosing</strong> – Specific INCS sprays include <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a>, <a class="drug drug_general" data-topicid="9125" href="/d/drug information/9125.html" rel="external">flunisolide</a>, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> propionate, <a class="drug drug_general" data-topicid="9663" href="/d/drug information/9663.html" rel="external">mometasone</a> furoate, fluticasone furoate, and <a class="drug drug_general" data-topicid="8537" href="/d/drug information/8537.html" rel="external">ciclesonide</a>. Doses and details about the specific preparations are reviewed in the table  (<a class="graphic graphic_table graphicRef55833" href="/d/graphic/55833.html" rel="external">table 3</a>). Several INCS sprays are available without a prescription. Differences in efficacy among INCS sprays have not been demonstrated [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– In general, INCS sprays are well tolerated by patients with CRSwNP. Nasal mucosal irritation can lead to mild epistaxis. Rare nasal septal perforation is an important adverse effect. Employing proper nasal spray technique and tapering to the lowest effective dose can reduce these risks  (<a class="graphic graphic_figure graphicRef141563" href="/d/graphic/141563.html" rel="external">figure 1</a>).</p><p></p><p class="headingAnchor" id="H2085486058"><span class="h5">Exhalation delivery system</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available products</strong> – A commercially available EDS (brand name: Xhance) with <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> propionate 93 mcg/spray is approved for treatment of CRSwNP in adults aged 18 years and older. The EDS uses a sealing nosepiece and flexible mouthpiece to administer the INCS with exhalation, which effectively increases the pressure in the sinonasal compartments. The patient places the pump into one nostril and blows forcefully into the mouthpiece of the device. The recommended daily dose is one spray in each nostril twice daily for a total dose of fluticasone propionate of 372 mcg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– It is reasonable to "step up" therapy to EDS-fluticasone in patients who have not benefitted from INCS sprays. Compared with INCS sprays, the EDS provides better medication deposition to the superior and posterior regions of the sinonasal cavity [<a href="#rid47">47</a>]. However, there is only indirect evidence comparing the efficacy of INCS sprays and the EDS. (See <a class="local">'Comparison of different delivery systems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific advantages of EDS</strong> – EDS-fluticasone is preferred by some patients with eustachian tube dysfunction who have increased symptoms of ear blockage with corticosteroid irrigations (see <a class="local">'Corticosteroid irrigations/drops'</a> below). It can also be more convenient for patients who travel frequently.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Similar to INCS sprays, common adverse reactions with the EDS include epistaxis, nasal septal ulceration, and nasal mucosal erythema [<a href="#rid48">48</a>]. In addition, close monitoring for glaucoma and cataracts is also recommended because of the higher doses of <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> delivered closer to the orbit. We advise patients to have yearly eye exams for this reason. In patients with a history of glaucoma or cataracts, we consult with the patient's ophthalmologist before using the EDS system.</p><p></p><p class="headingAnchor" id="H4146589659"><span class="h5">Corticosteroid irrigations/drops</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available products </strong>– In the United States, there are no Food and Drug Administration (FDA) approved intranasal steroid irrigations or drops. Corticosteroid irrigations/drops may help the medication reach the recesses of the nasal cavity, including the superior and posterior regions.</p><p></p><p class="bulletIndent1">Corticosteroid solutions, such as <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> and <a class="drug drug_general" data-topicid="9663" href="/d/drug information/9663.html" rel="external">mometasone</a> intended for use in nebulizers, can be diluted into <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and used to irrigate the sinuses (irrigations) or instilled undiluted directly into the nostrils (drops). Drops are uncommonly used and generally reserved for patients with more severe symptoms that do not adequately respond to irrigations or for acute exacerbations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – Corticosteroid irrigations, also referred to as rinses or flushes, involve adding an aqueous preparation of corticosteroid to the large-volume (ie,&gt; 200 mL per nostril) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> irrigations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Instructions for performing <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> nasal irrigations are described in the table  (<a class="graphic graphic_table graphicRef71059" href="/d/graphic/71059.html" rel="external">table 2</a>). Patients should add the prescribed corticosteroid solution to the amount of saline used each time, rather than make up a large amount of the solution and store it.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal drops can be administered using several head positions. It is not clear that head position impacts how well drops in surgery-naïve patients, while there is some evidence that head position improves efficacy in postsurgical patients [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– The safety of corticosteroid irrigations has been evaluated in several studies that did not find evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression, development of cataracts, or increased intraocular pressures, although studies only evaluated small numbers of patients [<a href="#rid50">50-53</a>]. In addition, it is possible that concurrent use of multiple topical steroid preparations (ie, INCS plus inhaled glucocorticoids for patients with CRSwNP and asthma) may lead to HPA axis suppression in some patients [<a href="#rid51">51</a>]. As with EDS-fluticasone, we recommend that patients using corticosteroid irrigations or drops have yearly eye exams. In patients with a history of glaucoma or cataracts, we consult with the patient's ophthalmologist before starting corticosteroid irrigations or drops.</p><p></p><p class="headingAnchor" id="H3431595255"><span class="h1">THERAPIES FOR SPECIFIC SITUATIONS</span><span class="headingEndMark"> — </span>Some patients may benefit from brief courses of oral glucocorticoids or oral antibiotics.</p><p class="headingAnchor" id="H3766098535"><span class="h2">Oral glucocorticoids for complete obstruction or severe symptoms</span><span class="headingEndMark"> — </span>Short courses of oral glucocorticoids can be used to temporarily shrink nasal polyps, which is helpful for patients who present with such severe nasal blockage that they cannot effectively use an intranasal corticosteroid (INCS) [<a href="#rid37">37,54,55</a>] or in the setting of severe symptoms of nasal congestion or anosmia.</p><p>We usually treat adults with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, 40 to 60 mg daily initially, and then gradually reduce the dose over 10 to 14 days. Doses are sometimes reduced for older adults or those who had adverse effects with previous use:</p><p class="bulletIndent1"><span class="glyph">●</span>One suggested regimen for adults is oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg for 5 days, followed by 20 mg daily for 5 days (10 days of treatment).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another, slightly longer regimen is 60 mg daily for 5 days, followed by 40 mg daily for 3 days, then 30 mg for 3 days, then 20 mg daily for 3 days (14 days of treatment).</p><p></p><p><a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">Methylprednisolone</a> can be used instead of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (8 mg of methylprednisolone is equivalent to 10 mg of prednisone).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-term efficacy</strong> – Multiple studies, including systematic reviews and randomized trials, have shown the substantial benefit of oral glucocorticoids in reducing nasal polyps size and improving sense of smell and sinonasal symptoms in the first two to three weeks after therapy [<a href="#rid54">54-57</a>]. However, by 10 to 12 weeks after the oral glucocorticoid course, the reduction in symptoms is not sustained in most patients [<a href="#rid54">54-56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guidelines regarding limited use</strong> – Repeated administrations of oral glucocorticoids should be avoided given the significant long-term side effects that can occur [<a href="#rid12">12</a>]. The requirement of two or more courses of oral glucocorticoids per year or long-term treatment with low-dose oral glucocorticoids were included as indications for biologic treatment for CRSwNP by an expert panel [<a href="#rid7">7</a>]. Significant adverse effects with short-term use are uncommon but can be serious, including hyperglycemia in people with diabetes or prediabetes, acute mood changes, and arrythmias. Patients should be counseled about these possibilities in advance. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_basics" href="/d/html/83983.html" rel="external">"Patient education: Oral steroid medicines (The Basics)"</a>.)</p><p></p><p class="bulletIndent1">In a patient who has recurrent disease despite a short course of oral glucocorticoids and sustained INCS use, alternative treatments such as functional endoscopic sinus surgery (FESS) or biologic therapy are recommended. (See <a class="local">'Functional endoscopic sinus surgery'</a> below and <a class="local">'Biologic therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H2744671886"><span class="h2">Oral antibiotics for superimposed infection</span><span class="headingEndMark"> — </span>Existing guidelines do not support the use of antibiotics for treatment of CRSwNP, except in the instance of acute infections [<a href="#rid12">12,15</a>]. CRSwNP is not primarily an infectious disorder, and, as such, antibiotics are not routinely used for management of chronic inflammation in CRSwNP. However, for some patients, uncontrolled sinonasal inflammation can predispose to recurrent or difficult-to-control infections, which may contribute to the persistence and severity of chronic disease.</p><p class="bulletIndent1"><span class="glyph">●</span>We reserve antibiotics for acute exacerbations of CRSwNP in which bacterial infection is suspected. We select an antibiotic based on culture of material obtained endoscopically from a sinus cavity whenever possible. (Note that cultures obtained by swabbing the nasal cavities generally reflect skin flora and are not useful.) If culture is not possible, then the choice of antibiotics is empiric and guided by additional factors such as local resistance patterns and potential for adverse effects. We usually give a 10- to 14-day course, occasionally extending it if the patient is not fully improved or purulence persists at the end of 14 days. Empiric choices of antibiotics for CRS are reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3412.html" rel="external">"Microbiology and antibiotic management of chronic rhinosinusitis", section on 'Empiric regimen selection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Staphylococcus aureus</em> has been identified in &gt;60 percent of patients with aspirin-tolerant CRSwNP and 80 percent of patients with aspirin-exacerbated respiratory disease (AERD) [<a href="#rid58">58</a>]. However, the evidence for use of antibiotics to eradicate <em>S. aureus</em> in the treatment of CRSwNP is lacking, and we do not give antibiotics for this reason.</p><p></p><p class="headingAnchor" id="H3395138878"><span class="h2">Antihistamines for patients with allergic rhinitis</span><span class="headingEndMark"> — </span>For patients with CRSwNP and concomitant allergic rhinitis, we administer nonsedating, second-generation antihistamines, such as <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> 10 mg orally twice daily. Cetirizine 20 mg daily for three months reduced rhinorrhea, sneezing, and, to a lesser extent, nasal congestion in a small, randomized, placebo-controlled trial of patients with CRSwNP with and without allergic rhinitis [<a href="#rid59">59</a>]. There was no effect on polyp size. Other therapies for patients with allergic rhinitis include antihistamine nasal sprays and combination corticosteroid/antihistamine nasal sprays. (See  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Antihistamine nasal sprays'</a> and  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Combination corticosteroid/antihistamine sprays'</a>.)</p><p class="headingAnchor" id="H79888484"><span class="h2">Aspirin therapy for AERD</span><span class="headingEndMark"> — </span>Patients with aspirin-exacerbated respiratory disease (AERD), the triad of adult-onset asthma, CRSwNP, and upper and/or lower respiratory reactions to nonsteroidal antiinflammatory drugs (NSAIDs), have particularly severe CRSwNP [<a href="#rid60">60,61</a>]. <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> desensitization and daily aspirin therapy is a treatment option that is only appropriate for patients with AERD. It is typically carried out by clinicians with experience in drug desensitization. Notably, aspirin therapy is not efficacious for patients with CRSwNP who do not have aspirin sensitivity. The management of AERD and aspirin desensitization are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a> and  <a class="medical medical_review" href="/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a>.)</p><p class="headingAnchor" id="H3121170996"><span class="h2">Antileukotriene agents for some patients with asthma</span><span class="headingEndMark"> — </span>Leukotriene-modifying agents include leukotriene receptor antagonists (ie, <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/d/drug information/10052.html" rel="external">zafirlukast</a>) and the 5-lipoxygenase inhibitor (<a class="drug drug_general" data-topicid="10054" href="/d/drug information/10054.html" rel="external">zileuton</a>)  (<a class="graphic graphic_table graphicRef77367" href="/d/graphic/77367.html" rel="external">table 4</a>). These agents are not approved specifically for the treatment of CRSwNP. However, they can be helpful with both sinonasal and pulmonary symptoms in some patients, although they are not adequate as monotherapy [<a href="#rid62">62-65</a>].</p><p>There are two subgroups of patients with asthma and CRSwNP who seem to benefit most consistently from antileukotriene agents: those with AERD and those with both asthma and allergic rhinitis. In such patients, we prescribe a three-month trial and assess for improvement in sinonasal and asthma symptoms; we discontinue treatment if there is no benefit in this timeframe.</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with AERD, we offer a trial of <a class="drug drug_general" data-topicid="10054" href="/d/drug information/10054.html" rel="external">zileuton</a>. AERD is a phenotype of CRSwNP marked by overproduction of cysteinyl leukotrienes [<a href="#rid66">66,67</a>]. In a randomized, placebo-controlled study of patients with AERD treated with zileuton or placebo for six weeks, zileuton-treated patients had improvement in smell and reductions in rhinorrhea and congestion compared with placebo-treated patients [<a href="#rid68">68</a>]. Dosing and administration of zileuton in AERD is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease", section on 'Leukotriene-modifying agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with coexistent asthma and allergic rhinitis sometimes benefit from <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a>, as shown in a small, prospective cohort study [<a href="#rid69">69</a>]. We offer a trial of montelukast or <a class="drug drug_general" data-topicid="10052" href="/d/drug information/10052.html" rel="external">zafirlukast</a>, which require less monitoring than <a class="drug drug_general" data-topicid="10054" href="/d/drug information/10054.html" rel="external">zileuton</a>.</p><p></p><p>There is a US Food and Drug Administration (FDA) boxed warning on <a class="drug drug_general" data-topicid="9539" href="/d/drug information/9539.html" rel="external">montelukast</a> advising that all patients should be warned about potential behavior and mood-related changes. In light of the boxed warning, we weigh risks and benefits of antileukotriene agents carefully for patients with CRSwNP prior to drug initiation. (See  <a class="medical medical_review" href="/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H2472851206"><span class="h1">CHOOSING BETWEEN SURGERY AND BIOLOGIC THERAPY</span><span class="headingEndMark"> — </span>In most cases, we refer surgery-naïve patients to an otolaryngologist for consideration of functional endoscopic sinus surgery (FESS) prior to initiation of a biologic therapy. The rationale for this preference is based upon a cohort study in which the efficacy of FESS was compared with that of three biologic therapies (<a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, and <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a>), as reported in randomized trials of each biologic compared with placebo [<a href="#rid70">70</a>]. A potential source of bias in this study was the significant drop off of FESS patients during follow-up. However, direct, head-to-head studies of surgery versus biologic therapy have not been done and likely will not be due to issues of consent and blinding.</p><p>The multicenter cohort study evaluated outcomes at 24 and 52 weeks in 111 patients with CRSwNP undergoing FESS (with subsequent medical therapy) after initial medical management proved insufficient [<a href="#rid70">70</a>]. At 24 weeks, FESS resulted in greater improvement in SNOT-22 scores than <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> (in one of two trials) and <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> (two of two trials). At 52 weeks, dupilumab and FESS yielded similar improvements in Sino-Nasal Outcomes Test (SNOT-22) scores. FESS was also more effective than <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a>. At both time points, FESS reduced polyp burden to a greater degree than the biologics (as would be expected). In addition, FESS appeared to be more cost effective than biologic therapy because biologics need to be continued indefinitely in theory [<a href="#rid71">71-74</a>].</p><p>Although we prefer FESS for most patients with CRSwNP before initiating a biologic therapy (see <a class="local">'Biologic therapies'</a> below), there are several important exceptions:</p><p class="bulletIndent1"><span class="glyph">●</span>Those with a contraindication to surgery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with such poorly controlled asthma that a biologic therapy is indicated for management of asthma regardless of sinus symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who decline surgery after shared decision making</p><p></p><p class="headingAnchor" id="H989137915"><span class="h1">SURGICAL MANAGEMENT</span><span class="headingEndMark"> — </span>This discussion of surgical management is focused on CRSwNP specifically. A more detailed discussion of the surgical management of CRS in general, including a description of the procedures, risks, and complications, is found separately. (See  <a class="medical medical_review" href="/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis", section on 'Functional endoscopic sinus surgery'</a>.)</p><p class="headingAnchor" id="H4013317439"><span class="h2">Functional endoscopic sinus surgery</span><span class="headingEndMark"> — </span>Functional endoscopic sinus surgery (FESS), when applied to patients with CRSwNP, is intended to remove polypoid material and inflammatory debris and maximize physiologic sinus ventilation and drainage to facilitate the gradual resolution of mucosal disease. In addition, widening of the outflow tracts allows for improved penetration by topical medications following surgery. Mucosal preservation is the universally accepted technique for both CRS with and without polyps to avoid excessive scarring and to maintain normal mucociliary clearance. In most cases, polyps within the olfactory cleft are only partially removed to avoid scarring of the olfactory epithelium and permanent smell loss. The changes that result from FESS are illustrated in the figure  (<a class="graphic graphic_figure graphicRef141534" href="/d/graphic/141534.html" rel="external">figure 2</a>). </p><p class="headingAnchor" id="H188963509"><span class="h3">Indications</span><span class="headingEndMark"> — </span>For most patients with CRSwNP, we offer sinus surgery when there is insufficient improvement with standard medical management. Specific indications for surgical intervention include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Failure of the initial medical therapies discussed above</p><p class="bulletIndent1"><span class="glyph">●</span>Severe symptoms or inability to use topical medication due to polyposis</p><p class="bulletIndent1"><span class="glyph">●</span>Bony erosion or extension of disease beyond the sinus cavities</p><p></p><p class="headingAnchor" id="H1554498842"><span class="h3">Safety and complications</span><span class="headingEndMark"> — </span>FESS for CRS of all types is safe in general, with minor complications in up to 6 percent and major complications in 1.5 percent [<a href="#rid75">75</a>]. Complication rates may be higher for CRSwNP than chronic rhinosinusitis without nasal polyposis (CRSsNP) since patients with severe polyp disease require more extensive surgery. Oral glucocorticoids prior to surgery are suggested in consensus statements to improve visualization of normal anatomy and reduce the propensity for bleeding in patients with CRSwNP [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3578764916"><span class="h2">Medical management after FESS</span><span class="headingEndMark"> — </span>Because functional endoscopic sinus surgery (FESS) does not directly treat the underlying inflammatory disorder, sinus surgery <strong>must</strong> be followed by medical therapy to control inflammatory processes, or symptoms will invariably return [<a href="#rid5">5</a>]. This typically consists of intranasal corticosteroid (INCS) sprays or irrigations. Studies of the efficacy of medical therapy in preventing regrowth of polyps are mixed, with some showing benefit [<a href="#rid76">76-79</a>] and others not [<a href="#rid79">79-81</a>]. In patients with CRSwNP, polyps usually reaccumulate within a few years without ongoing medical therapy, and they may recur despite it [<a href="#rid5">5,82</a>]. Patients with aspirin-exacerbated respiratory disease (AERD), in particular, may have recurrence of nasal polyposis following FESS, even with diligent INCS use [<a href="#rid83">83</a>].</p><p>The overall improvement in quality of life for patients with CRSwNP can be relatively long lasting after FESS and subsequent medical maintenance therapy. In several studies, improvements were sustained over five years, possibly due to the removal of significant obstructive symptoms related to polyps [<a href="#rid84">84,85</a>].</p><p class="headingAnchor" id="H4183066697"><span class="h2">Patients with polyp recurrence after FESS</span><span class="headingEndMark"> — </span>In patients with CRSwNP who begin to experience worsening symptom control and have evidence of polyp recurrence, options include biologic agents, more intensive INCS, or revision surgery for polyp removal.</p><p>More intensive INCS includes glucocorticoid irrigations (if not already tried), exhalation delivery system (EDS) <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a>, or glucocorticoid-eluting stents that are designed to be inserted in the ethmoid cavity after prior surgery has been performed. The stents can be placed under endoscopic guidance in the office setting. Clinical trials using this device have shown short-term efficacy [<a href="#rid86">86</a>], but no studies have directly compared these stents with glucocorticoids delivered by irrigations or EDS.</p><p class="headingAnchor" id="H2453747807"><span class="h1">BIOLOGIC THERAPIES</span><span class="headingEndMark"> — </span>Targeted biologic therapies are a newer treatment option for patients with CRSwNP  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>) [<a href="#rid13">13,87-90</a>]. Three have been approved by the US Food and Drug Administration (FDA) for CRSwNP: <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, and <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a>. The real-world and long-term use of biologics in CRSwNP is an area of active research.</p><p class="headingAnchor" id="H1328710648"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Most CRS guidelines suggest offering respiratory biologic therapy for patients who have previously undergone functional endoscopic sinus surgery (FESS) with recurrence of disease following surgery [<a href="#rid70">70,72-74</a>].</p><p>As mentioned above, the patients to whom we preferentially offer biologic therapy prior to surgery are:</p><p class="bulletIndent1"><span class="glyph">●</span>Those with a contraindication to surgery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with such poorly controlled asthma that biologic therapy is indicated for management of asthma regardless of sinus symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who decline surgery after shared decision making</p><p></p><p>The 2020 European position paper on rhinosinusitis proposed specific indications for biologic therapy for CRSwNP [<a href="#rid7">7</a>]. They were further modified in 2023 [<a href="#rid91">91</a>]. The authors identified biologic candidates as patients who had previously undergone FESS or were not candidates for FESS and met <strong>at least three of the five</strong> criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of type 2 inflammation (sinus tissue eosinophil count ≥10 eosinophils per high-powered field <strong>or</strong> peripheral blood eosinophils ≥150 cells/uL <strong>or</strong> total IgE ≥100 international units/mL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for oral glucocorticoids ≥2 courses per year <strong>or</strong> ≥3 months of low-dose oral glucocorticoids or a contraindication for systemic glucocorticoids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant impairment in quality of life (Sino-Nasal Outcomes Test [SNOT-22] score ≥40)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant loss of smell (anosmia on objective smell testing)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of comorbid asthma (requiring at least a regular controller inhaled glucocorticoid)</p><p></p><p class="headingAnchor" id="H1141767186"><span class="h2">Pretreatment testing</span><span class="headingEndMark"> — </span>We usually measure peripheral blood eosinophil counts and serum IgE levels, which are markers of type 2 inflammation, prior to initiation of biologic therapy as elevations in these parameters may help support the choice of biologic. In addition, therapy can modify these biomarkers, making it harder to assess them once the patient is on therapy. In patients with peripheral blood eosinophilia, nasal polyps, and asthma, it is important to consider the alternative diagnosis of eosinophilic granulomatosis with polyangiitis<strong> </strong>(EGPA) because treatment with a biologic may improve nasal and pulmonary symptoms and mask the underlying vasculitis. (See  <a class="medical medical_review" href="/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p class="headingAnchor" id="H3836784175"><span class="h2">Role of endotyping</span><span class="headingEndMark"> — </span>Endotypes refer to classifications of CRS based on pathophysiology and profiles of underlying inflammation, as determined by biomarkers and gene expression [<a href="#rid92">92</a>]. In contrast, phenotype refers to observable clinical characteristics. CRSwNP classifications based on phenotypes (eg, nonsteroidal antiinflammatory drug [NSAID] hypersensitivity in patients with aspirin-exacerbated respiratory disease [AERD]) can inform some management decisions for CRSwNP. However, phenotypic distinctions do not always reveal the underlying inflammatory mechanisms leading to CRSwNP, and respiratory biologics targeting type 2 inflammation are not uniformly efficacious in patients with CRSwNP [<a href="#rid93">93,94</a>].</p><p>In the US and Europe, CRSwNP is most frequently a type 2 inflammatory process characterized by type 2 cytokine production, tissue eosinophilia, mast cell infiltrates, type 2 innate lymphoid cells (ILC2s), and local IgE synthesis [<a href="#rid95">95,96</a>]. However, at the tissue level, some patients have type 1 inflammation (driven by interferon gamma and interleukin [IL] 12), type 3 inflammation (driven by IL-17), or mixed inflammatory endotypes [<a href="#rid96">96-98</a>].</p><p>Current guidelines for use of biologic therapy for treatment of CRSwNP recommend selecting patients with evidence of type 2 inflammation: tissue and peripheral blood eosinophil levels (polyp tissue eosinophils ≥10/high-power field <strong>or</strong> blood eosinophils ≥150 cells/mcL) and serum IgE levels (total IgE ≥100 international units/mL) [<a href="#rid7">7,91</a>] (see <a class="local">'Indications'</a> above). However, subgroup analyses of biologic therapy for the management of CRSwNP have shown efficacy of therapy regardless of baseline eosinophil level, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> sensitivity, comorbid asthma [<a href="#rid99">99</a>], or comorbid allergic rhinitis. Thus, further study is needed to define characteristics that predict which medication is most likely to be effective for a given patient.</p><p class="headingAnchor" id="H2532526432"><span class="h2">Selecting among biologic agents</span><span class="headingEndMark"> — </span>There are three "respiratory" (ie, effective for asthma) biologics that are also approved for treatment of CRSwNP in the United States and Europe: <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, and <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a>  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>). There are no completed head-to-head studies comparing these agents for treatment of CRSwNP. However, dupilumab was consistently found to be the most effective in multiple systematic reviews and indirect comparisons [<a href="#rid100">100-103</a>].</p><p>All three agents are approved for moderate-to-severe asthma. In addition, specific laboratory features and patient comorbidities can help to guide biologic selection; in patients with dual indications for biologic therapy such as atopic dermatitis, eosinophilic esophagitis, or chronic urticaria, the secondary indication can help direct the choice of a specific biologic. At present, the use of endotyping to guide selection of respiratory biologic agents requires further study [<a href="#rid104">104,105</a>]. (See <a class="local">'Role of endotyping'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 10 randomized trials of <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, and <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a> for CRS (nearly all of whom had CRSwNP), the investigators assessed the impact of biologic treatment on health-related quality of life as measured by the SNOT-22 score, disease severity, and serious adverse events. SNOT-22 scores improved 19.6 points with dupilumab, 15.6 points with omalizumab, and 13.3 points with mepolizumab [<a href="#rid103">103</a>]. The minimal clinically important difference (MCID) in the SNOT-22 score of 8.9 points was achieved for all three agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">Dupilumab</a> was superior to <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, except SNOT-22 scores were similar between the groups, in an indirect treatment comparison study of CRSwNP [<a href="#rid100">100</a>]. A head-to-head comparison of omalizumab versus dupilumab for treatment of CRSwNP is underway (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04998604&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSyhRUGxyD3%2FAio5zV0lmnDzxx9CMOg3Jwua08L8%2BmKfKA%3D%3D&amp;TOPIC_ID=121195" target="_blank">NCT04998604</a>).</p><p></p><p class="headingAnchor" id="H491150218"><span class="h3">Anti-IL-4RA (dupilumab)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">Dupilumab</a>, a monoclonal antibody targeting interleukin 4 receptor alpha (IL-4R-alpha), inhibits signaling of the cytokines IL-4 and IL-13, two pivotal drivers of type 2 inflammation that are important in diseases such as CRSwNP and asthma. Dupilumab reduces nasal congestion/blockage, endoscopic and radiologic sinus inflammation, rhinorrhea, postnasal drip, need for oral glucocorticoids, and need for FESS and improves sense of smell in patients with CRSwNP [<a href="#rid106">106,107</a>]. Dupilumab may be particularly efficacious in patients with AERD, as patients with AERD have near universal improvement with dupilumab [<a href="#rid108">108,109</a>]. As such, we typically choose dupilumab for patients with AERD who need biologic therapy for treatment of CRSwNP. It is also approved as a treatment for asthma, eosinophilic esophagitis, atopic dermatitis, and prurigo nodularis  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– Self-administered <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> 300 mg subcutaneously every 14 days is approved for treatment of CRSwNP. A loading dose is not indicated for treatment of CRSwNP  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>). Based on data from the SINUS-52 study [<a href="#rid106">106</a>], a real-world study [<a href="#rid110">110</a>], and our clinical experience, there are some patients that require less frequent dosing to achieve adequate symptom control, but this is off-label dosing. One author (KB) offers a three-month trial of every 28-day dosing to patients who have complete control of symptoms on an every 14-day regimen and no other comorbidities requiring more frequent dosing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> –<strong> </strong><a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">Dupilumab</a> is well tolerated by patients with CRSwNP. The most common side effects in the CRSwNP population include injection-site reactions, peripheral blood eosinophilia, insomnia, toothache, gastritis, arthralgias, and noninfectious conjunctivitis [<a href="#rid111">111</a>]. Preliminary reports have described an increased risk of developing several T helper type 17 (Th17) driven diseases, including seronegative arthritis, psoriasis, enthesitis/enthesopathy, and iridocyclitis in dupilumab-treated patients [<a href="#rid112">112,113</a>]. In our experience, these adverse effects improve when the drug is discontinued, but published data are lacking, and longer-term safety analyses are needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> –<strong> </strong>In two international, multicenter, phase-III studies of <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> in 724 patients with CRSwNP (SINUS-24 and SINUS-52), dupilumab significantly improved the co-primary endpoints, endoscopic measurement of nasal polyp size, the nasal polyp score (NPS), and patient-reported nasal congestion as measured by nasal congestion score (NCS) at 24 weeks [<a href="#rid106">106</a>]. Patients age 18 years and over were included if they had an endoscopic nasal polyp score of at least 5 (out of maximum of 8) despite treatment with intranasal corticosteroids (INCS), prior treatment with oral glucocorticoids or FESS within the two years preceding enrollment in the study, and inadequately controlled symptoms. More than 50 percent of patients in the study had comorbid asthma, and more than 25 percent had AERD. No specific eosinophil cutoff point was included for entry into the study.</p><p></p><p class="bulletIndent1">In terms of co-primary endpoints, the least squares mean difference in NPS for dupilumab-treated patients versus placebo was –2.06 (95% CI –2.43 to –1.69) and –1.80 (–2.10 to –1.51) in the SINUS-24 and 52 studies, respectively [<a href="#rid106">106</a>]. The least squares mean difference for NCS for dupilumab-treated patients versus placebo was –0.89 (–1.07 to –0.71) and –0.87 (–1.03 to –0.71) in the two studies. The dupilumab-treated patients also had improvement in objective smell testing scores, patient-reported sense of smell, radiologic sinus inflammation scores, and quality-of-life scores compared with placebo-treated patients. There was a 74 percent reduction in time to oral glucocorticoid use and an 83 percent reduction in time to FESS in the dupilumab-treated group compared with the placebo group.</p><p></p><p class="bulletIndent1">In SINUS-24, <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> was discontinued after 24 weeks, and some treatment effects (eg, NCS, NPS) showed signs of worsening by 12 weeks off therapy, highlighting the need for ongoing treatment. After 24 weeks of treatment in the SINUS-52 study, a subset of patients was transitioned to every 28-day dosing of dupilumab. They continued to have improvement in NPS and NCS compared with placebo [<a href="#rid106">106</a>].</p><p></p><p class="headingAnchor" id="H141004835"><span class="h3">Anti-IgE (omalizumab)</span><span class="headingEndMark"> — </span>Local immunoglobulin E (IgE) is present in nasal polyp tissue, and IgE levels are higher in patients with more severe CRSwNP [<a href="#rid95">95,114</a>]. Earlier observational studies and more recent randomized, placebo-controlled studies have shown that patients with CRSwNP treated with <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> have improvement in sinonasal symptoms and nasal polyp burden [<a href="#rid115">115-117</a>]. Omalizumab is also effective for allergic asthma and chronic spontaneous urticaria.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> –<strong> </strong>The anti-IgE monoclonal antibody <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> is approved by the US FDA for adult patients age 18 years and above as an add-on maintenance treatment of CRSwNP in patients with inadequate response to INCS and an IgE level of 30 to 1500 international units/mL  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>) [<a href="#rid116">116-118</a>]. Omalizumab is administered by subcutaneous injection every two to four weeks, with the dose determined based on body weight and serum IgE levels. Several guidelines recommend evaluating response to biologic therapy for CRSwNP after four to six months of treatment [<a href="#rid13">13,87,110</a>]. Omalizumab is available for in-office or at-home self-administration in the United States. Patients selected for self-administration of omalizumab should have no prior history of anaphylaxis to omalizumab or other agents such as food and drugs, should receive at least three doses of omalizumab in an observed setting without hypersensitivity reactions, should be able to recognize and treat anaphylaxis appropriately, and should be capable of performing subcutaneous injections with a prefilled syringe [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Home administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– In two replicate, phase-III studies (POLYP 1 and POLYP 2) of <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> as an add-on therapy to intranasal <a class="drug drug_general" data-topicid="9663" href="/d/drug information/9663.html" rel="external">mometasone</a> for 265 patients with inadequate response to INCS, co-primary endpoints (change from baseline to 24 weeks, NPS and NCS) were met, with statistically significant improvements at 24 weeks in NPS and NCS for omalizumab versus placebo. Improvements were observed as early as week 4 [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">In a pooled analysis of the two phase-III studies, a greater percentage of omalizumab-treated patients had a ≥1-point or (56.3 versus 28.7 percent) or ≥2-point (31.3 versus 11.6 percent) improvement in nasal polyp score compared with placebo [<a href="#rid117">117</a>]. A ≥1-point improvement in nasal congestion score was observed in a higher percentage of omalizumab-treated patients versus placebo-treated patients (44.4 versus 21.4 percent). In addition to reductions in NPS and NCS, omalizumab-treated patients had improvement in objective smell tests, quality-of-life measures, and patient-reported sense of smell, postnasal drip, and rhinorrhea compared with placebo. Specifically, SNOT-22 scores improved in both studies (-16.12 and -15.04 points in POLYP 1 and POLYP 2, respectively, with an MCID of 8.9). Scores of olfactory impairment were more modest, improving slightly less than 4 points on objective testing with the 40-item University of Pennsylvania Smell Identification Test (UPSIT; with an MCID generally regarded to be 4 points [<a href="#rid120">120</a>]).</p><p></p><p class="bulletIndent1">The studies above did not identify specific patient characteristics that predicted a good response to <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>. Subgroup analyses of the two phase-III studies of omalizumab for CRSwNP showed overall clinical improvement in terms of NCS, NPS, and other patient-reported outcomes in omalizumab-treated patients compared with placebo in patients with and without asthma, with and without prior sinonasal surgery, with and without <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> sensitivity, and regardless of blood eosinophil count (ie, &gt;300 and ≤300 cells/μL) [<a href="#rid121">121</a>]. Similarly, an earlier study found that both atopic and nonatopic patients with CRSwNP responded similarly to omalizumab [<a href="#rid116">116</a>]. In the 24-week open-label extension study, omalizumab discontinuation led to worsening of symptoms and NPS [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> for asthma and patient selection are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Efficacy'</a> and  <a class="medical medical_review" href="/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Indications and patient selection'</a>.)</p><p></p><p class="headingAnchor" id="H472800180"><span class="h3">Anti-IL-5 (mepolizumab)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">Mepolizumab</a> targets interleukin (IL) 5, a key survival and activation factor for eosinophils. Eosinophils are known to be elevated in nasal polyp tissue and play a role in the underlying inflammation causing CRSwNP [<a href="#rid123">123</a>]. Mepolizumab improves nasal congestion, overall quality of life, and NPS for patients with CRSwNP when compared with placebo [<a href="#rid93">93</a>]. It is also used for eosinophilic asthma, hypereosinophilic syndrome, and eosinophilic granulomatosis with polyangiitis (EGPA).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> –<strong> </strong><a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">Mepolizumab</a> 100 mg every four weeks is administered subcutaneously  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>). It can be administered in a medical facility or self-administered at home with a prefilled syringe or auto-injectors in appropriately trained patients [<a href="#rid124">124</a>]. The most common adverse effects reported in patients with CRSwNP are oropharyngeal pain and arthralgias. Herpes zoster infections have occurred in a small number of patients receiving mepolizumab for treatment of severe asthma. We administer the varicella-zoster vaccine to adults age 50 years or older four weeks prior to initiation of mepolizumab who otherwise have no contraindication to vaccination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> –<strong> </strong>A multinational, randomized, placebo-controlled phase-III study (SYNAPSE) included 414 patients with recurrent, severe bilateral nasal polyps and history of one prior FESS in the past 10 years. Patients received <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a> 100 mg subcutaneously or placebo every four week for 52 weeks in additional to standard-of-care <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> nasal irrigations and INCS. Mepolizumab-treated patients had decreased NPS (adjusted difference in median endoscopic NPS -0.73, 95% CI -1.11 to -0.34) and nasal obstruction visual analog scale score (-3.14, 95% CI -4.09 to -2.18) compared with placebo. However, sense of smell did not improve in mepolizumab-treated patients [<a href="#rid93">93</a>].</p><p></p><p class="headingAnchor" id="H4116534210"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Guidelines suggest that patients receiving a biologic therapy for CRSwNP be reevaluated four months after starting treatment, with monitoring at regular intervals thereafter [<a href="#rid7">7</a>]. Parameters that prescribers should monitor include improvement in quality of life and sense of smell, interim need for oral glucocorticoid use, reduction in nasal polyp size (if endoscopy can be performed), and impact on comorbidities such as asthma [<a href="#rid7">7,13</a>].</p><p class="headingAnchor" id="H2280127407"><span class="h2">Investigational biologic agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115768" href="/d/drug information/115768.html" rel="external">Benralizumab</a> and <a class="drug drug_general" data-topicid="134676" href="/d/drug information/134676.html" rel="external">tezepelumab</a>, which are both approved by the US FDA for treatment of severe asthma, are under investigation for treatment of CRSwNP [<a href="#rid125">125-127</a>].</p><p class="headingAnchor" id="H178791337"><span class="h1">TREATING ACUTE EXACERBATIONS</span><span class="headingEndMark"> — </span>Acute exacerbations of CRS have been defined as transient worsening of CRS that returns to baseline either without intervention or after intervention with antibiotics and/or systemic glucocorticoids [<a href="#rid7">7,11</a>]. The cause of acute exacerbations of CRSwNP is likely multifactorial and includes viral infections (likely the most frequent cause), bacterial infections, medication nonadherence, and allergen or irritant exposure.</p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics are frequently used to treat exacerbations of CRS, though the frequency that bacterial infections contribute to CRSwNP is unknown. When a bacterial infection is suspected (symptoms lasting more than seven days, purulent nasal drainage), we suggest an endoscopically obtained sinus culture, when possible, to guide antibiotic therapy. Patients with CRSwNP with uncomplicated bacterial infections can be treated similarly to an acute uncomplicated bacterial sinusitis  (<a class="graphic graphic_algorithm graphicRef106156" href="/d/graphic/106156.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For some patients with acute exacerbations, a 10- to 15-day tapering course of oral glucocorticoids provides sufficient relief of symptoms and allows the patient to return to their prior intranasal corticosteroid (INCS) regimen with control of symptoms. If patients are requiring frequent treatment with oral glucocorticoids for acute flares of CRSwNP, functional endoscopic sinus surgery (FESS) or biologic therapy should be considered to minimize long-term cumulative effects of oral glucocorticoid exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some patients, a brief escalation of therapy from a corticosteroid nasal spray to undiluted <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> respules can be sufficient to alleviate symptoms of an acute exacerbation (see <a class="local">'Corticosteroid irrigations/drops'</a> above). Following resolution of the acute exacerbation, the patient should return to their usual INCS delivery mode to minimize potential adverse effects of the concentrated budesonide.</p><p></p><p class="headingAnchor" id="H3432757043"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Long-term outcomes in patients with CRSsNP are poorly studied. An international registry has been established to collect data on the natural history of the disorder and treatment outcomes [<a href="#rid128">128</a>].</p><p class="headingAnchor" id="H2062052139"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110441.html" rel="external">"Society guideline links: Chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H2587573010"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83335.html" rel="external">"Patient education: Nasal polyps (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86637.html" rel="external">"Patient education: Chronic sinusitis (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86630.html" rel="external">"Patient education: How to rinse out your nose with salt water (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/378.html" rel="external">"Patient education: Chronic rhinosinusitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3099124441"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>–<strong> </strong>Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a complex inflammatory condition involving the paranasal sinuses and linings of the nasal passages, with the presence of nasal polyps, which lasts 12 weeks or longer. Symptoms include loss of the sense of smell (anosmia), nasal obstruction or blockage, anterior or posterior nasal drainage, and facial pressure. (See  <a class="medical medical_review" href="/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of care</strong> –<strong> </strong>Patient education is critical and involves setting realistic expectations for living with a condition that usually requires indefinite treatment, ensuring that patients use optimal technique for intranasal therapies, and establishing a daily routine of sinus care to which the patient can adhere long term. (See <a class="local">'Important components of care'</a> above.)</p><p></p><p class="bulletIndent1">Treatment can be started by a generalist, but the input of allergy/immunology and/or otolaryngology specialists is usually required. (See <a class="local">'Multidisciplinary collaboration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluate for coexisting conditions</strong> –<strong> </strong>There are several conditions that can present with CRSwNP but are important to recognize because they may impact treatment options and strategies, including aspirin-exacerbated respiratory disease (AERD), allergic rhinitis and asthma, and allergic fungal rhinosinusitis. Disorders that can present with similar symptoms and nasal polyposis but are treated differently include eosinophilic granulomatosis with polyangiitis (EGPA), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), and rare nasal tumors. (See <a class="local">'Coexisting disorders that may impact treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach </strong>– Our treatment approach is depicted in the algorithm and is consistent with multiple guidelines  (<a class="graphic graphic_algorithm graphicRef141882" href="/d/graphic/141882.html" rel="external">algorithm 1</a>). (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment </strong>– We suggest intranasal corticosteroids (INCS) as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). INCS are usually delivered via<strong> </strong>nasal sprays initially, in conjunction with daily <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> nasal irrigation  (<a class="graphic graphic_table graphicRef55833" href="/d/graphic/55833.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef71059" href="/d/graphic/71059.html" rel="external">table 2</a>). Limited data suggest that INCS provide modest benefit in most patients. It is uncertain which delivery system is best; thus, when patients have insufficient benefit from nasal sprays, we try other delivery systems, such as irrigations or exhalation delivery systems (EDS). (See <a class="local">'Intranasal corticosteroids'</a> above.)</p><p></p><p class="bulletIndent2">For patients with nasal obstruction that precludes the use of intranasal therapies, we suggest a short course of oral glucocorticoids prior to INCS (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Oral glucocorticoids shrink the polyps temporarily and allow INCS to penetrate the nasal passages better. However, the effect is always short lived, and repeated courses should be avoided because of the risk of long-term adverse effects. (See <a class="local">'Oral glucocorticoids for complete obstruction or severe symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who require additional therapy </strong>– When symptoms are not adequately controlled with INCS, we suggest functional endoscopic sinus surgery (FESS) rather than biologic therapy as the next step in treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). FESS is somewhat more effective for relief of symptoms, is less costly, and provides immediate improvement. The anatomic alterations resulting from FESS are illustrated in the figure  (<a class="graphic graphic_figure graphicRef141534" href="/d/graphic/141534.html" rel="external">figure 2</a>). FESS must be followed by maintenance INCS, or polyps will often grow back. (See <a class="local">'Choosing between surgery and biologic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of biologics </strong>– Biologic agents are a reasonable alternative to FESS for patients with severe or uncontrolled asthma who also need biologic therapy for their asthma, those with other conditions that could be simultaneously treated with a specific biologic, and those who refuse or cannot safely undergo surgery. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2">For patients with recurrent polyps after FESS, we suggest a biologic therapy rather than more intensive INCS therapy or revision sinus surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choosing among biologics </strong>– Three respiratory biologics are approved for treatment of CRSwNP in the United States and Europe: <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a>, and <a class="drug drug_general" data-topicid="105352" href="/d/drug information/105352.html" rel="external">mepolizumab</a>  (<a class="graphic graphic_table graphicRef140812" href="/d/graphic/140812.html" rel="external">table 5</a>). For most patients, we suggest dupilumab (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), except in patients who have concomitant chronic urticaria, for whom we choose omalizumab.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – Patients should be reevaluated every three to six months and assessed for improvements in quality of life, sense of smell, interim need for oral glucocorticoid use, reduction in nasal polyp size (if nasal endoscopy can be performed), and impact on comorbidities such as asthma. (See <a class="local">'Selecting among biologic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing acute exacerbations </strong>– CRSwNP can worsen periodically due to viral or bacterial infections, medication nonadherence, and allergen or irritant exposure. Symptoms sometime spontaneously return to baseline, but, if not, the choice of treatment (oral glucocorticoids, antibiotics, or a temporary change to a more intense form of INCS) depends on the clinical scenario as described above. (See <a class="local">'Treating acute exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– There is no known cure for CRSwNP, and long-term outcomes are poorly studied. Many patients require indefinite treatment. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sedaghat AR, Kuan EC, Scadding GK. Epidemiology of Chronic Rhinosinusitis: Prevalence and Risk Factors. J Allergy Clin Immunol Pract 2022; 10:1395.</a></li><li><a class="nounderline abstract_t">Phillips KM, Hoehle LP, Bergmark RW, et al. Acute Exacerbations Mediate Quality of Life Impairment in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract 2017; 5:422.</a></li><li><a class="nounderline abstract_t">Bhattacharyya N. Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy 2012; 26:120.</a></li><li><a class="nounderline abstract_t">Shen SA, Jafari A, Qualliotine JR, DeConde AS. Follow-Up Adherence Is Associated with Outcomes After Endoscopic Sinus Surgery. Ann Otol Rhinol Laryngol 2020; 129:707.</a></li><li><a class="nounderline abstract_t">Gosepath J, Pogodsky T, Mann WJ. Characteristics of recurrent chronic rhinosinusitis after previous surgical therapy. Acta Otolaryngol 2008; 128:778.</a></li><li><a class="nounderline abstract_t">Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy 2008; 38:260.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58:1.</a></li><li><a class="nounderline abstract_t">Hopkins C. Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med 2019; 381:55.</a></li><li><a class="nounderline abstract_t">Husain Q, Hoehle L, Phillips K, et al. The 22-Item Sinonasal Outcome Test as a Tool for the Assessment of Quality of Life and Symptom Control in Allergic Rhinitis. Am J Rhinol Allergy 2020; 34:209.</a></li><li><a class="nounderline abstract_t">Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2023; 151:386.</a></li><li><a class="nounderline abstract_t">Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 2021; 11:213.</a></li><li><a class="nounderline abstract_t">Borish L, Baroody FM, Kim MS, et al. Yardstick for the medical management of chronic rhinosinusitis. Ann Allergy Asthma Immunol 2022; 128:118.</a></li><li><a class="nounderline abstract_t">Roland LT, Smith TL, Schlosser RJ, et al. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop. Int Forum Allergy Rhinol 2020; 10:1037.</a></li><li><a class="nounderline abstract_t">Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol 2014; 113:347.</a></li><li><a class="nounderline abstract_t">Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 2016; 6 Suppl 1:S22.</a></li><li><a class="nounderline abstract_t">Chu DK, Lee DJ, Lee KM, et al. Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis. Int Forum Allergy Rhinol 2019; 9:1409.</a></li><li><a class="nounderline abstract_t">Benjamin MR, Stevens WW, Li N, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting. J Allergy Clin Immunol Pract 2019; 7:1010.</a></li><li><a class="nounderline abstract_t">Promsopa C, Kansara S, Citardi MJ, et al. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol 2016; 6:373.</a></li><li><a class="nounderline abstract_t">Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2017; 5:1061.</a></li><li><a class="nounderline abstract_t">Bachert C, Zhang N, Holtappels G, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol 2010; 126:962.</a></li><li><a class="nounderline abstract_t">AlQahtani A, Alim B, Almudhaibery F, et al. The Impact of Climatic, Socioeconomic, and Geographic Factors on the Prevalence of Allergic Fungal Rhinosinusitis: A Worldwide Ecological Study. Am J Rhinol Allergy 2022; 36:423.</a></li><li><a class="nounderline abstract_t">Ayoub N, Thamboo A, Habib AR, et al. Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis. Int Forum Allergy Rhinol 2017; 7:450.</a></li><li><a class="nounderline abstract_t">Gentile VG, Isaacson G. Patterns of sinusitis in cystic fibrosis. Laryngoscope 1996; 106:1005.</a></li><li><a class="nounderline abstract_t">Edafe O, Weight G, Morsy M, Mirza S. The incidence of significant pathology in patients presenting with benign-appearing unilateral nasal polyps. J Laryngol Otol 2022; 136:998.</a></li><li><a class="nounderline abstract_t">Thomas WW 3rd, Harvey RJ, Rudmik L, et al. Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations. Int Forum Allergy Rhinol 2013; 3:691.</a></li><li><a class="nounderline abstract_t">Chong LY, Head K, Hopkins C, et al. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4:CD011995.</a></li><li><a class="nounderline abstract_t">Pynnonen MA, Mukerji SS, Kim HM, et al. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg 2007; 133:1115.</a></li><li><a class="nounderline abstract_t">Wormald PJ, Cain T, Oates L, et al. A comparative study of three methods of nasal irrigation. Laryngoscope 2004; 114:2224.</a></li><li><a class="nounderline abstract_t">Succar EF, Turner JH, Chandra RK. Nasal saline irrigation: a clinical update. Int Forum Allergy Rhinol 2019; 9:S4.</a></li><li><a class="nounderline abstract_t">Keen M, Foreman A, Wormald PJ. The clinical significance of nasal irrigation bottle contamination. Laryngoscope 2010; 120:2110.</a></li><li><a class="nounderline abstract_t">Chiu AG, Palmer JN, Woodworth BA, et al. Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient. Am J Rhinol 2008; 22:34.</a></li><li><a class="nounderline abstract_t">Tulaci KG, Arslan E, Tulaci T, Yazici H. Comparison of effects of baby shampoo vs. saline irrigation on endoscopic sinus surgery outcomes and quality of life. Auris Nasus Larynx 2021; 48:408.</a></li><li><a class="nounderline abstract_t">Farag AA, Deal AM, McKinney KA, et al. Single-blind randomized controlled trial of surfactant vs hypertonic saline irrigation following endoscopic endonasal surgery. Int Forum Allergy Rhinol 2013; 3:276.</a></li><li><a class="nounderline abstract_t">Foster GR. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opin Pharmacother 2003; 4:685.</a></li><li><a class="nounderline abstract_t">Han JK, Bosso JV, Cho SH, et al. Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2021; 11:1407.</a></li><li><a class="nounderline abstract_t">Chong LY, Head K, Hopkins C, et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4:CD011996.</a></li><li><a class="nounderline abstract_t">Benítez P, Alobid I, de Haro J, et al. A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. Laryngoscope 2006; 116:770.</a></li><li><a class="nounderline abstract_t">Small CB, Hernandez J, Reyes A, et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol 2005; 116:1275.</a></li><li><a class="nounderline abstract_t">Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv 2012; 25:280.</a></li><li><a class="nounderline abstract_t">Aggarwal R, Cardozo A, Homer JJ. The assessment of topical nasal drug distribution. Clin Otolaryngol Allied Sci 2004; 29:201.</a></li><li><a class="nounderline abstract_t">Suman JD, Laube BL, Dalby R. Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. Pharm Res 1999; 16:1648.</a></li><li><a class="nounderline abstract_t">Bognanni A, Chu DK, Rank MA, et al. Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis. J Allergy Clin Immunol 2022; 150:1447.</a></li><li><a class="nounderline abstract_t">Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol 2019; 143:126.</a></li><li><a class="nounderline abstract_t">Sindwani R, Han JK, Soteres DF, et al. NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps. Am J Rhinol Allergy 2019; 33:69.</a></li><li><a class="nounderline abstract_t">Senior BA, Schlosser RJ, Bosso J, Soler ZM. Efficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays. Int Forum Allergy Rhinol 2021; 11:837.</a></li><li><a class="nounderline abstract_t">Chong LY, Head K, Hopkins C, et al. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4:CD011993.</a></li><li><a class="nounderline abstract_t">Leopold DA, Elkayam D, Messina JC, et al. EDS-FLU performs differently than other nasal corticosteroids. J Allergy Clin Immunol 2019; 144:349.</a></li><li class="breakAll">XHANCE (fluticasone propionate) nasal spray, for intranasal use. https://www.xhance.com/files/XHANCE_Full_Prescribing_Information.pdf (Accessed on January 05, 2023).</li><li><a class="nounderline abstract_t">Cummings EL, Fassas SN, Sykes KJ, et al. Positional Installation of Intranasal Corticosteroids in the Treatment of Chronic Rhinosinusitis: A Systematic Review of the Literature. Ear Nose Throat J 2021; 100:302.</a></li><li><a class="nounderline abstract_t">Smith KA, French G, Mechor B, Rudmik L. Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis. Int Forum Allergy Rhinol 2016; 6:228.</a></li><li><a class="nounderline abstract_t">Soudry E, Wang J, Vaezeafshar R, et al. Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery. Int Forum Allergy Rhinol 2016; 6:568.</a></li><li><a class="nounderline abstract_t">Dawson B, Gutteridge I, Cervin A, Robinson D. The effects of nasal lavage with betamethasone cream post-endoscopic sinus surgery: clinical trial. J Laryngol Otol 2018; 132:143.</a></li><li><a class="nounderline abstract_t">Man LX, Farhood Z, Luong A, et al. The effect of intranasal fluticasone propionate irrigations on salivary cortisol, intraocular pressure, and posterior subcapsular cataracts in postsurgical chronic rhinosinusitis patients. Int Forum Allergy Rhinol 2013; 3:953.</a></li><li><a class="nounderline abstract_t">Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Does oral prednisolone increase the efficacy of subsequent nasal steroids in treating nasal polyposis? Am J Rhinol Allergy 2012; 26:455.</a></li><li><a class="nounderline abstract_t">Vaidyanathan S, Barnes M, Williamson P, et al. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med 2011; 154:293.</a></li><li><a class="nounderline abstract_t">Ecevit MC, Erdag TK, Dogan E, Sutay S. Effect of steroids for nasal polyposis surgery: A placebo-controlled, randomized, double-blind study. Laryngoscope 2015; 125:2041.</a></li><li><a class="nounderline abstract_t">Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol 2010; 125:1069.</a></li><li><a class="nounderline abstract_t">Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 2004; 114:981.</a></li><li><a class="nounderline abstract_t">Haye R, Aanesen JP, Burtin B, et al. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol 1998; 112:1042.</a></li><li><a class="nounderline abstract_t">McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol 2006; 20:573.</a></li><li><a class="nounderline abstract_t">Bassiouni A, Wormald PJ. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope 2013; 123:36.</a></li><li><a class="nounderline abstract_t">Pauli C, Fintelmann R, Klemens C, et al. [Polyposis nasi--improvement in quality of life by the influence of leukotrien receptor antagonists]. Laryngorhinootologie 2007; 86:282.</a></li><li><a class="nounderline abstract_t">Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001; 31:1385.</a></li><li><a class="nounderline abstract_t">Stewart RA, Ram B, Hamilton G, et al. Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis. Otolaryngol Head Neck Surg 2008; 139:682.</a></li><li><a class="nounderline abstract_t">Schäper C, Noga O, Koch B, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 2011; 21:51.</a></li><li><a class="nounderline abstract_t">Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166:301.</a></li><li><a class="nounderline abstract_t">Dahlén B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 2000; 161:S137.</a></li><li><a class="nounderline abstract_t">Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187.</a></li><li><a class="nounderline abstract_t">Kieff DA, Busaba NY. Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol 2005; 114:941.</a></li><li><a class="nounderline abstract_t">Miglani A, Soler ZM, Smith TL, et al. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol 2023; 13:116.</a></li><li><a class="nounderline abstract_t">Scangas GA, Wu AW, Ting JY, et al. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope 2021; 131:E26.</a></li><li><a class="nounderline abstract_t">van der Lans RJL, Hopkins C, Senior BA, et al. Biologicals and Endoscopic Sinus Surgery for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: An Economic Perspective. J Allergy Clin Immunol Pract 2022; 10:1454.</a></li><li><a class="nounderline abstract_t">Rathi VK, Scangas GA, Metson RB, et al. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. Int Forum Allergy Rhinol 2022; 12:1295.</a></li><li><a class="nounderline abstract_t">Roland LT, Regenberg A, Luong AU, et al. Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics. Int Forum Allergy Rhinol 2021; 11:1524.</a></li><li><a class="nounderline abstract_t">Krings JG, Kallogjeri D, Wineland A, et al. Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope 2014; 124:838.</a></li><li><a class="nounderline abstract_t">Harvey RJ, Snidvongs K, Kalish LH, et al. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol 2018; 8:461.</a></li><li><a class="nounderline abstract_t">Kosugi EM, Moussalem GF, Simões JC, et al. Topical therapy with high-volume budesonide nasal irrigations in difficult-to-treat chronic rhinosinusitis. Braz J Otorhinolaryngol 2016; 82:191.</a></li><li><a class="nounderline abstract_t">Kang TW, Chung JH, Cho SH, et al. The Effectiveness of Budesonide Nasal Irrigation After Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Asthma. Clin Exp Otorhinolaryngol 2017; 10:91.</a></li><li><a class="nounderline abstract_t">Stjärne P, Olsson P, Alenius M. Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2009; 135:296.</a></li><li><a class="nounderline abstract_t">Dijkstra MD, Ebbens FA, Poublon RM, Fokkens WJ. Fluticasone propionate aqueous nasal spray does not influence the recurrence rate of chronic rhinosinusitis and nasal polyps 1 year after functional endoscopic sinus surgery. Clin Exp Allergy 2004; 34:1395.</a></li><li><a class="nounderline abstract_t">Rawal RB, Deal AM, Ebert CS Jr, et al. Post-operative budesonide irrigations for patients with polyposis: a blinded, randomized controlled trial. Rhinology 2015; 53:227.</a></li><li><a class="nounderline abstract_t">Li Y, Zhang GH, Liu X, et al. Clinical prognostic factors of chronic rhinosinusitis after endoscopic sinus surgery. ORL J Otorhinolaryngol Relat Spec 2008; 70:113.</a></li><li><a class="nounderline abstract_t">Rotenberg BW, Zhang I, Arra I, Payton KB. Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial. Laryngoscope 2011; 121:2702.</a></li><li><a class="nounderline abstract_t">Hopkins C, Slack R, Lund V, et al. Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope 2009; 119:2459.</a></li><li><a class="nounderline abstract_t">Simmonds JC, Paz-Lansberg M, Scangas G, Metson R. Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results. Int Forum Allergy Rhinol 2022; 12:257.</a></li><li><a class="nounderline abstract_t">Stolovitzky JP, Kern RC, Han JK, et al. In-office Placement of Mometasone Furoate Sinus Implants for Recurrent Nasal Polyps: A Pooled Analysis. Am J Rhinol Allergy 2019; 33:545.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019; 74:2312.</a></li><li><a class="nounderline abstract_t">Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol 2021; 147:29.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol 2020; 124:326.</a></li><li><a class="nounderline abstract_t">Kartush AG, Schumacher JK, Shah R, Patadia MO. Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps. Am J Rhinol Allergy 2019; 33:203.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 2023; 61:194.</a></li><li><a class="nounderline abstract_t">Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2013; 131:1479.</a></li><li><a class="nounderline abstract_t">Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:1141.</a></li><li><a class="nounderline abstract_t">Bachert C, Peters AT, Heffler E, et al. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. Clin Exp Allergy 2022; 52:244.</a></li><li><a class="nounderline abstract_t">Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 61:1280.</a></li><li><a class="nounderline abstract_t">Stevens WW, Peters AT, Tan BK, et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract 2019; 7:2812.</a></li><li><a class="nounderline abstract_t">Klingler AI, Stevens WW, Tan BK, et al. Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol 2021; 147:1306.</a></li><li><a class="nounderline abstract_t">Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol 2017; 139:699.</a></li><li><a class="nounderline abstract_t">Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol 2022; 149:1711.</a></li><li><a class="nounderline abstract_t">Peters AT, Han JK, Hellings P, et al. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract 2021; 9:2461.</a></li><li><a class="nounderline abstract_t">Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. Rhinology 2021; 59:151.</a></li><li><a class="nounderline abstract_t">Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol 2022; 149:1286.</a></li><li><a class="nounderline abstract_t">Chong LY, Piromchai P, Sharp S, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev 2021; 3:CD013513.</a></li><li><a class="nounderline abstract_t">Staudacher AG, Peters AT, Kato A, Stevens WW. Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis. Ann Allergy Asthma Immunol 2020; 124:318.</a></li><li><a class="nounderline abstract_t">Kato A, Peters AT, Stevens WW, et al. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy 2022; 77:812.</a></li><li><a class="nounderline abstract_t">Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394:1638.</a></li><li><a class="nounderline abstract_t">Bachert C, Mannent L, Naclerio RM, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA 2016; 315:469.</a></li><li><a class="nounderline abstract_t">Buchheit KM, Sohail A, Hacker J, et al. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2022; 150:415.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract 2019; 7:2462.</a></li><li><a class="nounderline abstract_t">van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, et al. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 2022; 77:670.</a></li><li class="breakAll">DUPIXENT (dupilumab) injection, for subcutaneous use. https://www.regeneron.com/downloads/dupixent_fpi.pdf (Accessed on December 04, 2022).</li><li><a class="nounderline abstract_t">Bridgewood C, Wittmann M, Macleod T, et al. T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. J Invest Dermatol 2022; 142:2660.</a></li><li><a class="nounderline abstract_t">Miss Ozuna L, Ryan T, Bensko JC, et al. Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2022; 128:469.</a></li><li><a class="nounderline abstract_t">Buchheit KM, Dwyer DF, Ordovas-Montanes J, et al. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2020; 145:1574.</a></li><li><a class="nounderline abstract_t">Vennera Mdel C, Picado C, Mullol J, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax 2011; 66:824.</a></li><li><a class="nounderline abstract_t">Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110.</a></li><li><a class="nounderline abstract_t">Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146:595.</a></li><li class="breakAll">US Food and Drug Administration. Xolair (omalizumab) approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/103976Orig1s5235ltr.pdf (Accessed on November 15, 2022).</li><li class="breakAll">Prescribing information for Xolair (omalizumab). https://www.gene.com/download/pdf/xolair_prescribing.pdf (Accessed on November 14, 2021).</li><li><a class="nounderline abstract_t">Doty RL, Yousem DM, Pham LT, et al. Olfactory dysfunction in patients with head trauma. Arch Neurol 1997; 54:1131.</a></li><li><a class="nounderline abstract_t">Damask C, Chen M, Holweg CTJ, et al. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis. Am J Rhinol Allergy 2022; 36:135.</a></li><li><a class="nounderline abstract_t">Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol 2022; 149:957.</a></li><li><a class="nounderline abstract_t">Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997; 99:837.</a></li><li class="breakAll">NUCALA (mepolizumab) for injection, for subcutaneous use. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF (Accessed on January 04, 2023).</li><li><a class="nounderline abstract_t">Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol 2022; 149:1309.</a></li><li class="breakAll">ClinicalTrials.gov. Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) (ORCHID). https://clinicaltrials.gov/ct2/show/NCT04157335 (Accessed on December 04, 2022).</li><li class="breakAll">ClinicalTrials.gov. Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). https://clinicaltrials.gov/ct2/show/NCT04851964 (Accessed on December 04, 2022).</li><li><a class="nounderline abstract_t">Seys SF, Hellings PW, Alobid I, et al. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology. J Allergy Clin Immunol Pract 2023; 11:431.</a></li></ol></div><div id="topicVersionRevision">Topic 121195 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35092822" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology of Chronic Rhinosinusitis: Prevalence and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27839750" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute Exacerbations Mediate Quality of Life Impairment in Chronic Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22487288" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32079413" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Follow-Up Adherence Is Associated with Outcomes After Endoscopic Sinus Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18568521" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characteristics of recurrent chronic rhinosinusitis after previous surgical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18167126" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : BSACI guidelines for the management of rhinosinusitis and nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32077450" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : European Position Paper on Rhinosinusitis and Nasal Polyps 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269366" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic Rhinosinusitis with Nasal Polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31684741" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The 22-Item Sinonasal Outcome Test as a Tool for the Assessment of Quality of Life and Symptom Control in Allergic Rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36370881" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33236525" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : International consensus statement on allergy and rhinology: rhinosinusitis 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687874" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Yardstick for the medical management of chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32484603" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25256029" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and management of rhinosinusitis: a practice parameter update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26889651" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31518069" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30368005" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26678021" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286156" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810157" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35187957" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Impact of Climatic, Socioeconomic, and Geographic Factors on the Prevalence of Allergic Fungal Rhinosinusitis: A Worldwide Ecological Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28218486" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8699890" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patterns of sinusitis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35513848" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The incidence of significant pathology in patients presenting with benign-appearing unilateral nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23729216" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115216" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Saline irrigation for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025315" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nasal saline for chronic sinonasal symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564850" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparative study of three methods of nasal irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31087631" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nasal saline irrigation: a clinical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824637" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The clinical significance of nasal irrigation bottle contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284857" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32859445" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of effects of baby shampoo vs. saline irrigation on endoscopic sinus surgery outcomes and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169768" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Single-blind randomized controlled trial of surfactant vs hypertonic saline irrigation following endoscopic endonasal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12739994" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34057824" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115217" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652085" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16337459" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of mometasone furoate nasal spray in nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22251061" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15142061" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The assessment of topical nasal drug distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10554112" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35970310" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29928924" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30477309" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970395" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115215" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Different types of intranasal steroids for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31076091" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : EDS-FLU performs differently than other nasal corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31076091" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : EDS-FLU performs differently than other nasal corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970499" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Positional Installation of Intranasal Corticosteroids in the Treatment of Chronic Rhinosinusitis: A Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26750509" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26879335" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893326" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effects of nasal lavage with betamethasone cream post-endoscopic sinus surgery: clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124056" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of intranasal fluticasone propionate irrigations on salivary cortisol, intraocular pressure, and posterior subcapsular cataracts in postsurgical chronic rhinosinusitis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23232195" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Does oral prednisolone increase the efficacy of subsequent nasal steroids in treating nasal polyposis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357906" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25945691" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of steroids for nasal polyposis surgery: A placebo-controlled, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20451040" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Oral steroids and doxycycline: two different approaches to treat nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480349" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197141" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effect of cetirizine on symptoms and signs of nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17181095" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Medical and surgical considerations in patients with Samter's triad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070897" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Role of frontal sinus surgery in nasal polyp recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17286243" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : [Polyposis nasi--improvement in quality of life by the influence of leukotrien receptor antagonists].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11591188" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984264" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Montelukast as an adjunct to oral and inhaled steroid therapy in chronic nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21370724" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153961" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673243" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of aspirin-intolerant asthma with antileukotrienes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563738" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16425561" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of montelukast in the treatment of nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980852" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243622" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35231626" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Biologicals and Endoscopic Sinus Surgery for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: An Economic Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35029845" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34250730" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122737" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29394004" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26431825" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Topical therapy with high-volume budesonide nasal irrigations in difficult-to-treat chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27440128" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The Effectiveness of Budesonide Nasal Irrigation After Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289710" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347372" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fluticasone propionate aqueous nasal spray does not influence the recurrence rate of chronic rhinosinusitis and nasal polyps 1 year after functional endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26363164" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Post-operative budesonide irrigations for patients with polyposis: a blinded, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408409" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical prognostic factors of chronic rhinosinusitis after endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997904" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19780032" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34510786" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31117809" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : In-office Placement of Mometasone Furoate Sinus Implants for Recurrent Nasal Polyps: A Pooled Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31090937" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : EUFOREA consensus on biologics for CRSwNP with or without asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33227318" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31830587" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Biologics in chronic rhinosinusitis with nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30587005" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36999780" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587334" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872587" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35092110" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17002703" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Differentiation of chronic sinus diseases by measurement of inflammatory mediators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31128376" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33326802" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639939" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35007624" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33548517" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33459728" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : State-of-the-art overview on biological treatment for CRSwNP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34543652" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33710614" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Biologics for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007571" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34473358" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31543428" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836729" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460728" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30954643" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34626497" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34626497" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395222" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35124224" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199912" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : IL-5Rαmarks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109700" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Efficacy of omalizumab in the treatment of nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021878" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32524991" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32524991" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32524991" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311357" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Olfactory dysfunction in patients with head trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382434" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34530020" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215253" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : IL-5 synthesis is upregulated in human nasal polyp tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215253" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : IL-5 synthesis is upregulated in human nasal polyp tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34599979" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34599979" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34599979" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36272718" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
